Global law firm Goodwin today announced that Michael Siekman has joined the firm's global Life Sciences practice as a partner in the Boston office.
"Michael's extensive background in patents, licensing, and intellectual property, particularly in PTAB proceedings, is a tremendous addition to our market-leading offering for life sciences companies and strengthens our capabilities to provide best-in-class guidance on litigation matters," said Mitchell Bloom, Chair of Goodwin's Life Sciences practice. "We are thrilled to welcome Michael to the firm during this critical time for protecting life sciences-related IP for industry innovators."
Michael advises clients in the biotechnology, biosimilar, and pharmaceutical industries on a range of intellectual property matters, including patent prosecution and portfolio strategy, licensing, post-grant proceedings, and litigation. He has more than 25 years of experience that has included developing patent portfolio for several pioneering biotechnologies. Michael has successfully argued before the Patent Trial and Appeal Board (PTAB) and has secured several favorable opposition outcomes before the European Patent Office. His transactional practice involves licensing agreements, collaboration agreements, and IP-related aspects of mergers, acquisitions, IPOs and other financings.
Goodwin's Life Sciences practice works with companies throughout the corporate lifecycle – from startup and commercial-stage to maturity – as well as investors, banks, and others in the life sciences ecosystem. The firm's life sciences patent lawyers, patent agents and technical staff help assure that the best intellectual property strategy is in place to position and secure intellectual property protection, including patent protection, of our client's core technology and lead therapeutic moieties, including small molecules, biologics, formulations, delivery systems, companion diagnostics, and medical devices. All of Goodwin's life sciences patent portfolio lawyers hold advanced degrees spanning chemistry, biology and other life science technologies.